Results From Clinical Trials With KEYTRUDA® (pembrolizumab): Advanced Melanoma
Melanoma

RESULTS FROM CLINICAL TRIALS WITH KEYTRUDA

Advanced melanoma

Living longer with advanced melanoma is possible

A clinical trial compared patients with advanced melanoma who received 10 mg/kg of KEYTRUDA every 2 weeks (279 patients) or 3 weeks (277 patients) with those who received ipilimumab (278 patients).

KEYTRUDA helped certain patients with melanoma live longer compared to another immunotherapy*

More patients treated with KEYTRUDA were alive at the time of follow-up compared to patients treated with ipilimumab. 33% (92 of 277 patients) treated with KEYTRUDA every 3 weeks were not alive at follow-up, compared to 40% (112 of 278 patients) treated with ipilimumab. KEYTRUDA given every 3 weeks was shown to reduce the risk of dying by 31% compared to ipilimumab.

*KEYTRUDA was compared to ipilimumab.

100%
0%
67%
60%
185 out of 277 patients were alive
166 out of 278 patients were alive

KEYTRUDA

Ipilimumab

KEYTRUDA helped shrink melanoma tumors

100%
0%
33%
12%
91 out of 277 patients had their tumors shrink
33 out of 278 patients had their tumors shrink

KEYTRUDA

Ipilimumab

Partial Response: 27%

(74 out of 277 patients)

Partial Response: 10%

(29 out of 278 patients)

Complete Response: 6%

(17 out of 277 patients)

Complete Response: 1%

(4 out of 278 patients)

In Advanced Melanoma, KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Progression by 42% Compared to Ipilimumab

In advanced melanoma, KEYTRUDA reduced the risk of disease progression by 42% compared to ipilimumab

KEYTRUDA given every 3 weeks reduced the risk of cancer spreading, growing, or getting worse by 42% compared to ipilimumab.

Half of the patients on KEYTRUDA given every 3 weeks were alive without their cancer spreading, growing, or getting worse at 4.1 months, compared to 2.8 months for patients on ipilimumab.

How KEYTRUDA compared to chemotherapy for advanced melanoma

Another clinical trial compared patients with advanced melanoma who received KEYTRUDA every 3 weeks with those who received chemotherapy.

Nearly 5 times as many patients on KEYTRUDA saw their melanoma tumors shrink compared to chemotherapy

100%
0%
21%
4%
38 out of 180 patients had their tumors shrink
8 out of 179 patients had their tumors shrink

KEYTRUDA

Chemotherapy

Partial Response: 19%

(34 out of 180 patients)

All of these patients saw partial responses and no complete responses were seen.

Complete Response: 2%

(4 out of 180 patients)

KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Progression in Advanced Melanoma by 43% Compared to Chemotherapy

KEYTRUDA reduced the risk of disease progression by 43% compared to chemotherapy

Half of the patients on KEYTRUDA were alive without their cancer spreading, growing, or getting worse at 2.9 months, compared to 2.7 months for patients on chemotherapy.

FDA-Approved Indications

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma. KEYTRUDA may be used:

  • when your melanoma has spread or cannot be removed by surgery (advanced melanoma), or
  • to help prevent your melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
Important Safety Information

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen any time during treatment or even after your treatment has ended.

Call or see your health care provider right away if you develop any signs or symptoms of the following problems or if they get worse. These are not all of the signs and symptoms of immune system problems that can happen with KEYTRUDA:

Lung problems: cough, shortness of breath, or chest pain.

Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); or bleeding or bruising more easily than normal.

Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness.

Kidney problems: decrease in the amount of your urine; blood in your urine; swelling of your ankles; loss of appetite.

Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in your mouth or in your nose, throat, or genital area; fever or flu-like symptoms; swollen lymph nodes.

Problems can also happen in other organs and tissues. Signs and symptoms of these problems may include: chest pain; irregular heartbeat; shortness of breath; swelling of ankles; confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs; double vision; blurry vision; sensitivity to light; eye pain; changes in eyesight; persistent or severe muscle pain or weakness; muscle cramps; low red blood cells; bruising.

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feeling like passing out, fever, and back pain.

Rejection of a transplanted organ: Your health care provider should tell you what signs and symptoms you should report and they will monitor you, depending on the type of organ transplant that you have had.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your health care provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your health care provider will check you for these problems during treatment with KEYTRUDA. They may treat you with corticosteroid or hormone replacement medicines. They may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Before you receive KEYTRUDA, tell your health care provider if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or have had or plan to have a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic); have had radiation treatment in your chest area; have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.

If you are pregnant or plan to become pregnant, tell your health care provider. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, you will be given a pregnancy test before you start treatment. Use effective birth control during treatment and for at least 4 months after your final dose of KEYTRUDA. Tell them right away if you think you may be pregnant or you become pregnant during treatment with KEYTRUDA.

Tell your health care provider if you are breastfeeding or plan to breastfeed. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Common side effects of KEYTRUDA when used alone include feeling tired; pain, including pain in muscles, bones or joints and stomach area (abdominal) pain; decreased appetite; itching; diarrhea; nausea; rash; fever; cough; shortness of breath; and constipation.

In children, when KEYTRUDA is used alone, fever, vomiting, upper respiratory tract infection, headache, and low levels of white blood cells and red blood cells (anemia) are more common than in adults.

Common side effects of KEYTRUDA when given with certain chemotherapy medicines include feeling tired or weak; nausea; constipation; diarrhea; decreased appetite; rash; vomiting; cough; trouble breathing; fever; hair loss; inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs; swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; mouth sores; and headache.

Common side effects of KEYTRUDA when given with axitinib include diarrhea; feeling tired or weak; high blood pressure; liver problems; low levels of thyroid hormone; decreased appetite; blisters or rash on the palms of your hands and soles of your feet; nausea; mouth sores or swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; hoarseness; rash; cough; and constipation.

These are not all the possible side effects of KEYTRUDA. Talk to your health care provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the accompanying Medication Guide for KEYTRUDA and discuss it with your doctor. The physician Prescribing Information also is available.